Dimension Therapeutics (NASDAQ: DMTX) expects to raise $82.5 million in its upcoming IPO. Based in Cambridge, Massachusetts, Dimension Therapeutics is a biotechnology company with a gene therapy platform for developing treatments for rare diseases associated with the liver.

We previewed DMTX on our IPO Insights Platform last week.

Dimension Therapeutics will offer 5.5 million shares at an expected price range of $14 to $16. If the underwriters price the IPO at the midpoint of that range, DMTX will have a market capitalization of $373 million.

DMTX filed for the IPO on September 14, 2015.

Lead Underwriters: Citigroup Global Markets and Goldman Sachs

Underwriters: Cannacord Genuity, Cantor Fitzgerald and Wells Fargo Securities

Business Summary: Biotech with Gene Therapy Platform

Dimension Therapeutics is a biotechnology company with a gene therapy platform for developing treatments that target rare liver diseases and other disorders caused by genetic mutations. The company’s lead product candidate is DTX01, which is a gene therapy designed to deliver Factor IX gene expression for individuals with hemophilia B. Other products include DTX301, a gene therapy product candidate to treat individuals with a deficiency of ornithine transcarbamylase; DTX201, a gene therapy to treat patients with hemophilia A; and DTX401, a gene therapy treatment for individuals with a specific variation of a glycogen storage disorder.

(click to enlarge)

(Source)

In August 2015, the company submitted an Investigational New Drug application (IND) to the FDA for its lead product candidate, DTX101, for the treatment of hemophilia B. In September, Dimension Therapeutics received the green light to proceed with Phase I/II clinical trials of DTX101. In addition, DTX101 received Orphan Drug Designation and Fast Track Designation for treating hemophilia B. Currently, the company intends to initiate those clinical trials by the end of this year.